MAP2K7 and neoplasm: The simultaneous use of inhibitors targeting RAS/MEK and mTORC1/2 leads to long-lasting and effective suppression of PDAC tumour growth, and it also overcomes the development of resistance to the individual drugs (Brown et al. 2020).